News about "Zealand Pharma "

Zealand Pharma and Roche to Develop and Commercialize Petrelintide

Zealand Pharma and Roche to Develop and Commercialize Petrelintide

The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist.

Zealand Pharma | 15/03/2025 | By Aishwarya


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members